Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1Phase 1/2 1

Status

Terminated 1Recruiting 1Completed 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 2Head & Neck 1

Conditions

Carcinoma, Non-Small-Cell Lung 2Squamous Cell Carcinoma of Head and Neck 1Head and Neck Neoplasms 1Adenocarcinoma of Lung 1

Interventions

pembrolizumab 1270Specimen Handling 870Carboplatin 831Magnetic Resonance Spectroscopy 808Cyclophosphamide 802Cisplatin 728Nivolumab 658Paclitaxel 631Radiotherapy 573Gemcitabine 572Biopsy 529Bevacizumab 475Dexamethasone 440fludarabine 407Docetaxel 378venetoclax 370Oxaliplatin 365Capecitabine 356Fluorouracil 354atezolizumab 341durvalumab 334Rituximab 332Doxorubicin 316Radiosurgery 309Pemetrexed 305Drug Therapy 302Ipilimumab 294Standard of Care 293Etoposide 285Radiation 279

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Interventional × bemcentinib × 1 year × Clear all
NCT07445048 2026-04-17

Postoperative Radiotherapy Combined With Nimotuzumab Followed by Benmelstobart in High-Risk Patients With Head and Neck Squamous Cell Carcinoma

Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University

Phase 3 Recruiting
370 enrolled
Head & Neck

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT05469178 2025-10-29

A Clinical Study of Bemcentinib With Standard of Care Chemoimmunotherapy in Untreated Advanced/Metastatic Non-small Cell Lung Cancer Patients With a Mutation in the STK11 Gene

BerGenBio ASA

Phase 1/2 Terminated
26 enrolled 13 charts
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT03184571 2025-09-25

Bemcentinib (BGB324) in Combination With Pembrolizumab in Patients With Advanced Non-small Cell Lung Cancer (NSCLC)

BerGenBio ASA

Phase 2 Completed
99 enrolled 20 charts
Thoracic

Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡